Abstract Number: PB0854
Meeting: ISTH 2022 Congress
Background: Bleeding complications in thrombocytopenic patients constitute a significant problem in clinical practice. Current laboratory approaches fail to evaluate hemostasis in thrombocytopenia and also the efficacy of platelet transfusion. The Total Thrombus Formation Analysis System (T-TAS) is a new approach proposed to explore hemostasis in samples with low platelet counts. T-TAS may become an alternative tool to explore the hemostatic effect of hemoderivatives.
Aims: To validate T-TAS as a suitable device to evaluate hemostasis in samples from thrombocytopenic patients before and after platelet transfusion. To explore the hemostatic efficiency of in vitro addition of Thrombosomes®, a human platelet-derived lyophilized hemostatic agent proposed for the treatment of bleeding in thrombocytopenia.
Methods: Whole blood from hematological thrombocytopenic patients (n=28) (platelet count < 30x10^3 platelets/µl) was collected before and after platelet transfusion. Hemostasis was evaluated through T-TAS, with specific chips (HD) containing microcapillary channels (50-μm-deep) coated with collagen and tissue factor. Area under the curve (AUC) and occlusion times (OT, min) were registered for both samples before and after addition of Thrombosomes® (50x10^3/µl).
Results: Values (Mean±SEM) of platelet counts were of 10±1.2 and 24±2 (x10^3 platelets/µl) and hematocrits (HCT) were of 24±0.6% and 27±1%, before and after platelet transfusion, respectively. T-TAS demonstrated significant improvements after platelet transfusion (see Table 1). Addition of Thrombosomes® increased AUC and shortened OT in 60% and 100% of samples from non-transfused (p˂0.05) and transfused patients, respectively.
Conclusion(s): The newly designed system T-TAS, using a modified microchip-based flow chamber, was able to measure hemostasis in samples with thrombocytopenia and low hematocrit. T-TAS was useful to evaluate the hemostatic capacity of transfused platelets. Moreover, T-TAS offers a platform to assess the hemostatic effect of hemoderivatives, such as Thrombosomes®, which enabled hemostasis even in those samples in which it was severely impaired.
To cite this abstract in AMA style:Samanbar S, Moreno-Castaño A, Piñeyroa J, Pino M, Torramade-Moix S, Martinez-Sanchez J, Moskowitz K, Escolar G, Diaz-Ricart M. Evaluation of the hemostatic ability of the new device Total Thrombus Formation Analysis System’ (T-TAS) for thrombocytopenic patients. In vitro effect of Thrombosomes® [abstract]. https://abstracts.isth.org/abstract/evaluation-of-the-hemostatic-ability-of-the-new-device-total-thrombus-formation-analysis-system-t-tas-for-thrombocytopenic-patients-in-vitro-effect-of-thrombosomes/. Accessed October 1, 2023.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-the-hemostatic-ability-of-the-new-device-total-thrombus-formation-analysis-system-t-tas-for-thrombocytopenic-patients-in-vitro-effect-of-thrombosomes/